Core Points - The company, Beijing Hotgen Biotech Co., Ltd., has announced a share repurchase plan approved by its board of directors on November 11, 2025 [1][2] - The announcement includes details about the top ten shareholders and the top ten unrestricted shareholders as of the day before the board meeting [1] Group 1: Share Repurchase Plan - The board of directors approved a share repurchase plan via centralized bidding [1] - The details of the repurchase plan were disclosed on November 12, 2025, on the Shanghai Stock Exchange and other designated media [1] Group 2: Shareholder Information - The announcement includes the names, shareholdings, and ownership percentages of the top ten shareholders [1] - It also provides information on the top ten unrestricted shareholders, although specific data is not detailed in the announcement [1]

Investment Rating - The report indicates a positive outlook for the CXO and research services sectors within the pharmaceutical industry, suggesting continued high growth potential [2][3]. Core Insights - The pharmaceutical industry saw a slight decline in sales revenue and a modest increase in net profit for Q3 2025 compared to Q3 2024, with revenue growth rates of -0.1% and net profit growth of 3.0% [2][16]. - The fastest-growing segments in terms of revenue for Q3 2025 were CXO, research services, and pharmaceuticals, while the fastest-growing segments for net profit were research services, CXO, and pharmacies [2][24]. - The report emphasizes the importance of innovative drugs, highlighting that 58 selected innovative drug companies in A-shares experienced a revenue growth of 1.4% and a net profit decline of 4.5% year-on-year for the first three quarters of 2025 [2][28]. - The research services sector showed significant improvement, with a revenue growth of 10.48% and net profit growth of 49.57% in Q3 2025 compared to Q3 2024, indicating a recovery in demand and market conditions [2][3]. Summary by Sections 1. Pharmaceutical Industry - The overall profitability of the pharmaceutical industry showed a slight improvement in Q3 2025, with a net profit margin increase compared to the same period in 2024 [7][17]. 2. Innovative Drugs - Innovative drug companies reported a revenue growth of 3.3% and a net profit decline of 15.0% in Q3 2025, with a focus on companies like Heng Rui Medicine and Rejane Bio [2][28]. 3. Traditional Chinese Medicine - The revenue and net profit growth for traditional Chinese medicine companies remained under pressure, with Q3 2025 showing a revenue decline of 1.1% year-on-year [2][3]. 4. Pharmaceuticals - The pharmaceutical sector experienced a revenue growth of 5.6% and a net profit growth of 12.5% in Q3 2025, indicating a recovery phase [2][3]. 5. Research Services - The research services sector demonstrated strong growth, with a revenue increase of 10.48% and net profit increase of 49.57% in Q3 2025, reflecting a positive market trend [2][3]. 6. Medical Services - Medical services companies faced challenges, with a slight revenue decline of 0.29% in Q3 2025, indicating ongoing pressure from macroeconomic factors [2][3]. 7. Medical Devices - The medical device sector reported a revenue growth of 3.30% in Q3 2025, with expectations for recovery in demand in the coming year [2][3]. 8. Biological Products - The biological products sector continued to face challenges, with a revenue decline of 14.5% in Q3 2025 compared to Q3 2024 [3]. 9. CXO - The CXO sector showed robust growth, with revenue increasing by 11.74% and net profit by 47.47% in Q3 2025, driven by improved market conditions [3]. 10. Raw Materials - The raw materials sector experienced a revenue decline of 8.2% in Q3 2025, influenced by geopolitical factors and reduced domestic demand [3]. 11. Pharmacies - Pharmacy companies reported a revenue growth of 1.9% in Q3 2025, with a focus on profit growth [3]. 12. Pharmaceutical Distribution - The pharmaceutical distribution sector showed a revenue growth of 1.7% in Q3 2025, with increasing industry concentration [3].

证券代码：688068 证券简称：热景生物 公告编号：2025-081 北京热景生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日召开了第四届董事会第六次会议，审议通过了《关于以集中竞价交易方式回购 股份方案的议案》，具体内容详见公司于 2025 年 11 月 12 日在上海证券交易所 网站及公司指定信息披露媒体披露的《关于以集中竞价交易方式回购股份方案的 公告》（公告编号：2025-077）。 北京热景生物技术股份有限公司 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，现将公司董事会公告回购股份决议的前一个交易日（即 2025 年 11 月 11 日）登记在册的前十名股东和前十名无限售条件股东的名称、持股数量和持股比 例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 林长青 | 20,682,487 | 22.31 | | 2 | 周锌 | 5,009,649 | 5.40 | | 3 | 北京热景生物技术股份有限公司 回购专用证券账户 | 3,8 ...

Core Viewpoint - The implementation of the "Guidelines for the Supervision of Listed Companies No. 10 - Market Value Management" has led to a significant increase in the use of various market value management tools by listed companies, including cash dividends, share buybacks, mergers and acquisitions, and equity incentives, to enhance investment value and return to investors [1][2]. Group 1: Market Value Management Tools - Cash dividends and share buybacks have become frequently used tools in the market value management toolbox, with companies encouraged to establish clear mechanisms for share repurchase and to develop and disclose medium- to long-term dividend plans [1][2]. - As of October 31, 2023, 1,195 companies in China's stock market have announced 1,525 share buyback plans for 2025, with a total buyback amount of 92.3 billion yuan, of which 36% was funded by self-owned capital and 26% was for cancellation [2]. - The total cash dividend amount across the market reached 734.9 billion yuan, with 89 companies distributing over 1 billion yuan in dividends within the year [2]. Group 2: Mergers and Acquisitions - The past year has seen a vibrant M&A market, particularly in the "hard technology" sector, with notable cases such as the acquisition of 72.33% of Chip Alliance's shares and the merger of Haiguang Information with Zhongke Shuguang [3]. - State-owned enterprises are also actively engaging in professional integration, exemplified by China Shenhua's plan to consolidate 13 energy companies and Guotai Junan's merger with Haitong Securities [3]. - Policy support has been a key driver for the active M&A market, with various reforms and guidelines aimed at enhancing the efficiency and vitality of mergers and acquisitions [3]. Group 3: Equity Incentives - Equity incentives have been highlighted as a significant market value management tool, with companies encouraged to establish long-term incentive mechanisms [4][5]. - By mid-2023, nearly 3,500 listed companies had implemented equity incentive or employee stock ownership plans, representing 64% of all A-share listed companies [5]. - The recognition of equity incentives as a market value management strategy has deepened, with more companies expected to adopt these tools to enhance long-term value [5].

投资者可于 2025 年 11 月 17 日（星期一）至 11 月 21 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hotgen@ hotgen.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京热景生物技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 24 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 24 日（星期一） 11:00-12:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 证券代码：688068 证券简称：热景生物 公告编号：2025-080 北京热景生物技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 会议召开方式：上证路演中心网络互动 三、参加人员 本次投资者说明会以网络互动形式召开 ...

Group 1 - A-share market opened lower and fluctuated, with the medical sector showing overall activity, particularly the medical device ETF (562600) which rose by 0.22% and has seen net inflows for 12 consecutive trading days [1] - Leading stocks in the medical device sector include Reborn Medical and Lide Medical, both of which rose over 10%, while Hualan Co., Bairen Medical, and Innotec also showed strong performance [1] - Lide Medical announced a major asset purchase plan to acquire 70% of Xiansheng Xiangrui for a transaction price of 1.733 billion yuan, constituting a significant asset restructuring as the target assets exceed 50% of the listed company's total assets [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) effectively capturing structural growth opportunities in the core medical fields [2] - The ETF tracks the CSI All Index Medical Device Index, which includes 100 representative listed companies in medical devices, medical services, and medical information technology [2] - Investors can also consider alternative options such as the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient investment [2]

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount between RMB 100 million and RMB 200 million, aimed at employee stock ownership plans or equity incentives [2][31]. Group 1: Repurchase Plan Details - Total repurchase amount: Not less than RMB 100 million and not more than RMB 200 million [2][31]. - Source of funds: Self-owned funds [3][17]. - Purpose of repurchase: To be used for employee stock ownership plans or equity incentives [3][10]. - Price cap for repurchase: Not exceeding RMB 244.00 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [3][16]. - Method of repurchase: Centralized bidding trading method [4][11]. - Duration of repurchase: Within 12 months from the board's approval date [5][12]. Group 2: Implementation and Compliance - The board approved the repurchase plan on November 11, 2025, with unanimous support from all directors present [7][9]. - The repurchase plan does not require shareholder meeting approval as per relevant regulations [8][9]. - The company has established a dedicated securities account for the repurchase [28]. Group 3: Progress of Repurchase - As of November 12, 2025, the company has repurchased 202,540 shares, representing 0.2185% of the total share capital, with a total expenditure of approximately RMB 30 million [33]. - The lowest purchase price was RMB 145.59 per share, and the highest was RMB 152.18 per share [33]. Group 4: Future Plans and Governance - The company will continue to monitor market conditions and make repurchase decisions accordingly, ensuring compliance with relevant regulations [28][33]. - There are currently no clear plans for share reduction by major shareholders or executives in the next three to six months [5][21].

Core Viewpoint - The company, Hotgen Biotech, announced its first share buyback on November 12, 2025, through centralized bidding, repurchasing 202,540 shares, which represents 0.2185% of its total share capital [1] Summary by Categories - **Share Buyback Announcement** - Hotgen Biotech conducted its initial share buyback, acquiring 202,540 shares [1] - The repurchased shares account for 0.2185% of the company's total equity [1]

Group 1 - The company, Hotgen Biotech (SH 688068), announced its first share repurchase on November 12, 2025, buying approximately 200,000 shares, which represents 0.2185% of its total share capital, with a total expenditure of about 30.01 million yuan [1] - The repurchased shares were acquired at a minimum price of 145.59 yuan per share and a maximum price of 152.18 yuan per share [1] - For the year 2024, the company's revenue composition is heavily weighted towards in vitro diagnostic products, which account for 98.85% of total revenue, while other businesses contribute only 1.15% [1] Group 2 - As of the report, Hotgen Biotech has a market capitalization of 15.8 billion yuan [1]

证券代码：688068 证券简称：热景生物 公告编号：2025-078 北京热景生物技术股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 相关股东是否存在减持计划：公司董事、高管、控股股东、实际控制人及一致 行动人、持股 5%以上的股东未来 3 个月、未来 6 个月暂无明确的减持计划；如上 述人员后续有相关减持股份计划，公司将按照法律、法规、规范性文件的要求及 时行信息披露义务。 ● 相关风险提示： 1、本次回购股份存在回购期限内公司股票价格持续超出回购方案披露的价格上限， 导致回购方案无法顺利实施的风险； 2、若公司在实施回购股份期间，受外部环境变化、临时经营需要等因素影响，致 使本次回购股份所需资金未能筹措到位，可能存在回购方案无法实施或者部分实 施的风险； 3、若发生对公司股票交易价格产生重大影响的重大事项，或公司生产经营、财务 情况、外部客观情况发生重大变化，或其他导致董事会终止本次回购方案的事项 ● 回购股份金额：回购资金总额不低于人民币 ...